Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.

ABSTRACT:

Background

Temsirolimus is a mammalian target of rapamycin (mTOR) inhibitor with single-agent antitumour activity in patients with mantle cell lymphoma. We therefore tested its efficacy and toxicity in combination with rituximab (an antiCD20 antibody) in patients with relapsed or refractory mantle cell lymphoma.

Methods

In a phase 2 study, patients (aged ≥18 years) at 35 centres in the USA were given temsirolimus 25 mg/week, and rituximab 375 mg/m(2) per week for 4 weeks during the first cycle and thereafter a single dose of rituximab every other 28-day cycle. Both drugs were administered intravenously. Responding patients after six cycles could continue treatment for a total of 12 cycles, and were then observed without additional maintenance treatment. The primary endpoint

SUBMITTER: Ansell SM 

PROVIDER: S-EPMC3106222 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature